HIV Cure

Clinical Trial

Most Recent Clinical Trial Update

Feb 25, 2024

American Gene Technologies® has completed our Phase 1 clinical trial and we have submitted the final report to the FDA. In the meantime, we are designing the Phase 2 clinical trial protocol and working to identify manufacturers and trial sites. As we review the Phase 1 data with potential collaborators and partners, the response has been consistently enthusiastic about the early data. The analytic treatment interruption has already highlighted impressive viral suppression and immunological data.

We hope to initiate the Phase 2 clinical trial as soon as the new protocol is approved. Pending FDA approval of the Phase 2, data-collection should complete late 2024 or early 2025.

Follow new clinical trial developments on Facebook and Twitter.

HIV Clinical Trial Timeline


HIV Cure Countdown

American Gene Technologies is making great progress in our ongoing HIV clinical trial. Here is a countdown from when we first started this journey in 2019 to 2022. We highlight key milestones we’ve achieved so far, as well as future developments we are working toward — all in an effort to potentially cure HIV.


Share on Social Media

05_AGT Cure Countdown Page graphic

Phase 1 Began

October 2020

American Gene Phase 1 trial officially opened and started seeking trial participants.

07_AGT Cure Countdown Page graphic

First Product Passes Release Testing 

April 2021

After Phase 1 began and the trial participants were enrolled, American Gene manufactured AGT103-T and passed an extensive panel of safety testing.

08_AGT Cure Countdown Page graphic

First Patient Infused

May 2021

The very first trial participant received an infusion of AGT103-T.

09_AGT Cure Countdown Page graphic

Three Patients with No Serious Adverse Events; DSMB Accelerates Trial

November 2021

After no serious adverse events were recorded from the first 3 patients, the DSMB voted unanimously to continue the program at a faster pace. The 4th and 5th patient were treated in November 2021.

10_AGT Cure Countdown Page graphic

First Five Patients Show Critical Efficacy Markers

February 2022

The AGT103-T gene and cell therapy was tested on participants, giving us a sneak peek at efficacy data that normally occurs in Phase 2. The initial data showed blood markers of efficacy in all five clinical trial participants.

12_AGT Cure Countdown Page graphic

First Human Efficacy


Given that participants in the study are living with HIV and have been given a therapeutic dose of the experimental drug, American Gene may actually see some patients go into durable remission and be able to go off of their ARTs.

13_AGT Cure Countdown Page graphic

Phase 2 Approved


A successful Phase 1 will lead to a Phase 2 study, which could be pivotal. Gene and cell therapies frequently get limited license in a Phase 2 study. 

14_AGT Cure Countdown Page graphic

Phase 2 Completed


Successful completion of a Phase 2 study may give us the ability to apply for a limited license, sometimes referred to as a BLA. The FDA will consider whether sufficient safety has been shown, and if efficacy is attractive.

15_AGT Cure Countdown Page graphic

Biologics License Agreement (BLA)


We’re hopeful that our clinical successes will merit a license. Provided the successful clinical studies, the BLA will allow American Gene Technologies to offer the therapy commercially. 

Have Questions? Get Answers.

Visit our knowledge base for answers to FAQs about American Gene Technologies' HIV cure program and Phase 1 clinical trial.

How Does AGT103-T Work?

Watch our CEO break down American Gene Technologies' gene and cell therapy strategy for curing HIV.

As we work toward the next milestone in the HIV Cure Program, learn more about the history of HIV that has been developing over the last 40 years.